Brind.

Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.

Steady: 1 in the last 7 days Updated monday

The latest in this situation

  1. FDA grants approval for Ziihera, driving its U.S. market launch.
  2. Jazz Pharmaceuticals presented trial results at the ESMO Congress.

How it started

3 reports, 0 independent, last reported Jul 6. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.

Who's involved

What this event is mainly about
Jazz PharmaceuticalsIcelandNorwayLiechtensteinEurope

How it developed

Newest first. Tap a step to see who reported it.
  1. Jazz Pharmaceuticals plans U.S. launch of Ziihera.Sub-event
  2. Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.Sub-event
  3. Jazz Pharmaceuticals gains conditional marketing authorization in Europe and specific country approvals for Ziihera.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet